Immatics N.V. (IMTX) vs Replimune Group, Inc. (REPL)

Immatics N.V. and Replimune Group, Inc. are both Biotechnology companies. Immatics N.V. and Replimune Group, Inc. are of similar size ($1.3B and $1.2B). Replimune Group, Inc. has the higher net margin (0.00% vs −489.4%) and the lower return on invested capital (−1,154.7% vs −84.8%). Across the 14 metrics below, Immatics N.V. leads on 9 and Replimune Group, Inc. on 5.

Valuation

Metric IMTX REPL Biotechnology median
P/E n/m n/m 7.88
P/S 23.25 n/m 11.47
P/B 2.46 11.37 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 17.76 n/m 10.73
Earnings yield (22.22%) (25.40%) (28.84%)
Free cash flow yield (21.01%) (23.36%) (23.03%)

Profitability

Metric IMTX REPL Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (536.26%) 0.00% 0.00%
Net margin (489.35%) 0.00% 0.00%
Free cash flow margin (488.01%) 0.00% 0.00%
Return on equity (48.53%) (134.29%) (57.72%)
Return on assets (39.83%) (82.28%) (49.22%)
Return on invested capital (84.83%) (1,154.69%) 0.00%

Growth

Metric IMTX REPL Biotechnology median
Revenue growth (TTM) (64.99%) — 5.64%
EPS growth (last fiscal year) (1,313.33%) (10.10%) —
Revenue growth, 5-year CAGR 11.81% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMTX REPL Biotechnology median
Debt to equity 0.00 1.00 0.00
Current ratio 7.54 5.23 4.73
Net debt to EBITDA 2.04 0.51 0.96

Dividend

Metric IMTX REPL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMTX REPL Biotechnology median
Market cap 1.26b 1.20b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack